NICE and Colorectal Cancer Treatment
Author Information
Author(s): Mark P Saunders, J W Valle
Primary Institution: Christie Hospital
Hypothesis
Why hasn't NICE followed North America and Europe's lead in recommending more widespread use of effective drugs for colorectal cancer?
Conclusion
The editorial argues that NICE's guidance on colorectal cancer treatment is outdated and limits patient access to effective therapies.
Supporting Evidence
- NICE's guidance limits the use of newer, more effective treatments for colorectal cancer.
- Patients in the UK may have a reduced life expectancy due to these restrictions.
- Evidence from large trials supports the use of irinotecan in first-line treatment.
Takeaway
The NICE guidelines for treating colorectal cancer are not as good as those in other countries, which means patients in the UK might not get the best treatments.
Potential Biases
Potential bias in treatment recommendations due to cost considerations.
Limitations
The editorial discusses the limitations of NICE's recommendations based on retrospective data and the lack of clear patient definitions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website